Form 4: SpringWorks Therapeutics COO Edris Badreddin Sells Shares

Edris Badreddin, Chief Operating Officer of SpringWorks Therapeutics, sold a total of 19,920 shares of common stock in multiple transactions on September 3, 2024, under a pre-arranged trading plan.

Summary

• On September 3, 2024, Edris Badreddin, the Chief Operating Officer of SpringWorks Therapeutics, sold 12,300 shares of common stock at a weighted average price of $40.1145.
• An additional 4,620 shares were sold at a weighted average price of $41.1158.
• Finally, 3,080 shares were sold at a weighted average price of $42.075.
• These sales were executed under a pre-arranged trading plan (Rule 10b5-1) adopted on February 29, 2024.
• Following these transactions, Mr. Badreddin directly owns 229,600 shares of SpringWorks Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock sales by an executive. It doesn't inherently convey positive or negative sentiment, as the sales were pre-planned.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It provides transparency into the trading activities of company executives, which is important for investors to monitor.

Stakeholder Impact

• The stock sale by a key executive could be perceived negatively by some shareholders, although the existence of a pre-arranged trading plan mitigates this concern.

Key Dates